2026 – Patient Worthy

Targeted Immunomodulation Transforms Dermatomyositis Management: Phase 3 Brepocitinib Trial Demonstrates Significant Clinical Benefits

Post author:Bree Clare
Post published:April 16, 2026
Post category:Dermatomyositis

Researchers have demonstrated substantial therapeutic benefits for brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, in adults with dermatomyositis, according to findings from a Phase 3 clinical trial published…

Akebia Doses First Volunteers in Phase 1 Study of AKB-9090 for Surgery-Related AKI

Post author:Austin Newman
Post published:April 15, 2026
Post category:IgA Nephropathy (IgAN)

Akebia Therapeutics has initiated clinical development of a new investigational therapy aimed at preventing or treating acute kidney injury (AKI) associated with cardiac surgery. The company announced that the first…

Triple Negative Breast Cancer: A Breakthrough Treatment

Post author:Rose Duesterwald
Post published:April 15, 2026
Post category:Triple-negative breast cancer

Triple negative breast cancer, the most aggressive form of breast cancer, is under attack. Adelaide University researchers, led by Dr. Theresa Hinkey, report that unlike chemotherapy, the pill only targets…

Combinatorial Immunotherapy Strategy: CatalYm Advances Visugromab in Advanced Liver Cancer

Post author:Bree Clare
Post published:April 15, 2026
Post category:Hepatocellular Carcinoma

CatalYm has initiated patient enrollment in the GDFATHER-HCC-01 trial, a Phase 2b study investigating visugromab as part of a combinatorial treatment strategy for patients with unresectable or metastatic hepatocellular carcinoma…

Litifilimab Shows Promise in Phase 2 Trial for Cutaneous Lupus

Post author:Austin Newman
Post published:April 14, 2026
Post category:Lupus

Phase 2 data suggest meaningful skin improvement and an acceptable safety profile As reported on Healio, litifilimab, an investigational therapy developed by Biogen, demonstrated encouraging efficacy and tolerability in patients…

A Smarter Urine Test for Bladder Cancer

Post author:Kathy Devanny
Post published:April 14, 2026
Post category:Bladder cancer

As reported on Inside Precision Medicine, Researchers at Stanford have created a new urine test that helps doctors understand how well bladder cancer treatments are working. Usually, bladder cancer is…

Strategic Reassessment: Roche Discontinues Emugrobart in Spinal Muscular Atrophy and FSHD

Post author:Bree Clare
Post published:April 14, 2026
Post category:Muscular Dystrophy

Chugai Pharmaceutical Co., Ltd. announced that Roche has made the strategic decision to discontinue clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin antibody, for two neuromuscular conditions: spinal muscular…

Amgen Reports Positive Phase 3 Data for Subcutaneous Tepezza in Thyroid Eye Disease

Post author:Austin Newman
Post published:April 13, 2026
Post category:Thyroid eye disease

As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults with moderate-to-severe active thyroid eye…

Living in Fear of Pain Can Make Pain Worse

Post author:Tom Seaman
Post published:April 13, 2026
Post category:Cervical Dystonia

Most of us have heard of the fight-or-flight stress response. It becomes activated when we believe there is a chance we can outfight or outrun real or perceived danger and…

Revolutionary Approach to Triple-Negative Breast Cancer: Telomir-1 Advances Toward Clinical Trials

Post author:Bree Clare
Post published:April 13, 2026
Post category:Triple-negative breast cancer

Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology's most challenging cancers. As reported by Pharmaceutical Technology, the company…

What Happens When a Patient Is Living with Multiple Rare Diseases?

Post author:Patient Worthy Contributor
Post published:April 12, 2026
Post category:Rare Disease

I have battled several autoimmune and neurological conditions that are triggered by food and other factors for over 50 years. It took most of my life to reach not one,…

Reimagining HIV Treatment: When Monthly Clinic Visits Outperform Daily Pills

Post author:Bree Clare
Post published:April 11, 2026
Post category:HIV/AIDS

The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model increasingly conflicts with the complex…

Phase 3 VALOR Trial Shows Brepocitinib Improves Outcomes in Dermatomyositis

Post author:Austin Newman
Post published:April 10, 2026
Post category:Dermatomyositis

As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal of Medicine, marking a significant…

Can We Fix This Broken Heart? – Part 5

Post author:Patient Worthy Contributor
Post published:April 10, 2026
Post category:Congestive Heart Failure

Editor's Note: Patient Worthy is pleased to share the final part in a series of excerpts by Dana Langston. Chapter 36: Holding the Line Knowing the surgery won't happen until…

A Breakthrough for the Invisible Affliction: FDA Approves First-Ever Treatment for Cholestatic Itch in Liver Disease

Post author:Bree Clare
Post published:April 10, 2026
Post category:Primary Biliary Cholangitis

For patients living with primary biliary cholangitis (PBC), a rare autoimmune liver disease, an often-overlooked symptom has plagued their existence, an intense, maddening internal itch that cannot be relieved by…

EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer

Post author:Austin Newman
Post published:April 9, 2026
Post category:Rare Disease

As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with unresectable hepatocellular carcinoma (HCC), according…

Can We Fix This Broken Heart? – Part 4

Post author:Patient Worthy Contributor
Post published:April 9, 2026
Post category:Congestive Heart Failure

Editor's Note: Patient Worthy is pleased to share part 4 of 5 in a series of excerpts written by Dana Langston. Part 7: Legacy & Final Gratitude Chapter 25: The…

Breaking Through Depression’s Barriers: Real-World Evidence Demonstrates Spravato’s Long-Term Effectiveness

Post author:Bree Clare
Post published:April 9, 2026
Post category:Major Depressive Disorder

When standard depression medications fail, patients face a devastating reality. Approximately one-third of people with major depressive disorder do not adequately respond to conventional antidepressants, leaving them trapped in a…

Subcutaneous Tepezza Matches Infusion in Phase 3 Trial, Amgen Reports

Post author:Austin Newman
Post published:April 8, 2026
Post category:Thyroid eye disease

As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the new formulation performs similarly to…

Can We Fix This Broken Heart? – Part 3

Post author:Patient Worthy Contributor
Post published:April 8, 2026
Post category:Rare Disease

Editor's Note: Patient Worthy is proud to bring you part 3 of 5 in a series of excerpts written by Dana Langston. Part 3: The Mental Battlefield Chapter 12: Doing…

Next-Generation Eye Treatment OLN324 Demonstrates Superior Performance in Major Clinical Trial

Post author:Bree Clare
Post published:April 8, 2026
Post category:Wet macular degeneration

Ollin Biosciences has announced important clinical trial results showing that OLN324, an investigational eye treatment, outperforms an existing therapy in treating two serious retinal diseases that threaten vision in millions…

Alkermes Launches Phase 3 Program for Investigational Narcolepsy Therapy Alixorexton

Post author:Austin Newman
Post published:April 7, 2026
Post category:Narcolepsy

As reported on Business Wire, Alkermes plc has initiated a global phase 3 clinical development program to evaluate alixorexton, an investigational oral therapy for people living with narcolepsy type 1…

Can We Fix This Broken Heart? – Part 2

Post author:Patient Worthy Contributor
Post published:April 7, 2026
Post category:Rare Disease

Editor's Note: This is the second part in a series of excerpts written by Dana Langston. Chapter 4: The Internal Shift We are living in the "waiting room" now. The…

A New Hope for Treatment-Resistant Multiple Myeloma: CellCentric Advances InoPd into Pivotal Clinical Testing

Post author:Bree Clare
Post published:April 7, 2026
Post category:Multiple Myeloma

Multiple myeloma, a cancer of plasma cells in the bone marrow, has become an increasingly manageable disease over the past two decades, thanks to successive waves of innovative therapies. However,…

Gilead Ends Midstage HIV Study as FDA Clinical Hold Continues

Post author:Austin Newman
Post published:April 6, 2026
Post category:HIV/AIDS

As reported on FierceBioTech, Gilead Sciences has closed one of its midstage clinical studies evaluating an experimental HIV regimen, following ongoing safety concerns that prompted U.S. regulators to intervene last…

Targeted Immunomodulation Transforms Dermatomyositis Management: Phase 3 Brepocitinib Trial Demonstrates Significant Clinical Benefits

Akebia Doses First Volunteers in Phase 1 Study of AKB-9090 for Surgery-Related AKI

Triple Negative Breast Cancer: A Breakthrough Treatment

Combinatorial Immunotherapy Strategy: CatalYm Advances Visugromab in Advanced Liver Cancer

Litifilimab Shows Promise in Phase 2 Trial for Cutaneous Lupus

A Smarter Urine Test for Bladder Cancer

Strategic Reassessment: Roche Discontinues Emugrobart in Spinal Muscular Atrophy and FSHD

Amgen Reports Positive Phase 3 Data for Subcutaneous Tepezza in Thyroid Eye Disease

Living in Fear of Pain Can Make Pain Worse

Revolutionary Approach to Triple-Negative Breast Cancer: Telomir-1 Advances Toward Clinical Trials

What Happens When a Patient Is Living with Multiple Rare Diseases?

Reimagining HIV Treatment: When Monthly Clinic Visits Outperform Daily Pills

Phase 3 VALOR Trial Shows Brepocitinib Improves Outcomes in Dermatomyositis

Can We Fix This Broken Heart? – Part 5

A Breakthrough for the Invisible Affliction: FDA Approves First-Ever Treatment for Cholestatic Itch in Liver Disease

EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer

Can We Fix This Broken Heart? – Part 4

Breaking Through Depression’s Barriers: Real-World Evidence Demonstrates Spravato’s Long-Term Effectiveness

Subcutaneous Tepezza Matches Infusion in Phase 3 Trial, Amgen Reports

Can We Fix This Broken Heart? – Part 3

Alkermes Launches Phase 3 Program for Investigational Narcolepsy Therapy Alixorexton

Can We Fix This Broken Heart? – Part 2

A New Hope for Treatment-Resistant Multiple Myeloma: CellCentric Advances InoPd into Pivotal Clinical Testing

Gilead Ends Midstage HIV Study as FDA Clinical Hold Continues

Let’s Work Together!

Keep Up to Date

Learn More